HALOZYME THERAPEUTICS, INC. Convertible Notes Payable
HALOZYME THERAPEUTICS, INC. (HALO) had Convertible Notes Payable of $1.51 billion as of 2022-12-31, per its 10-K filed 2023-02-21.
Discontinued › Balance Sheet › Liabilities
us-gaap:ConvertibleNotesPayable · last filed 2023-02-21
- 2022-12-31: Convertible Notes Payable $1.51B.
- 2022-06-30: Convertible Notes Payable $878.62M.
- 2022-03-31: Convertible Notes Payable $877.64M.
- 2021-12-31: Convertible Notes Payable $876.67M.
| Period end | Convertible Notes Payable |
|---|---|
| 2022-12-31 | $1.51B 10-K · filed 2023-02-21 |
| 2022-06-30 | $878.62M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $877.64M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $876.67M 10-K · filed 2023-02-21 |
| 2021-09-30 | $875.71M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $874.74M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $873.77M 10-Q · filed 2021-05-10 |
| 2021-01-01 | $449.79M 10-K · filed 2022-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |